Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

836
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
836
Development of Immunocompetence01:22

Development of Immunocompetence

669
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
669
Vaccinations01:51

Vaccinations

50.9K
Overview
50.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

218
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
218

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens.

Clinical microbiology reviews·2026
Same author

Overcoming methicillin resistance in Staphylococcus aureus via metal ion disruption of bacterial metabolism.

npj antimicrobials and resistance·2026
Same author

Molecular characterization of covRS mutations in M1<sub>UK</sub> Streptococcus pyogenes.

FEBS open bio·2026
Same author

Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus.

The Journal of antimicrobial chemotherapy·2026
Same author

Emergence of distinct Streptococcus pyogenes emm1 and emm12 lineages in China.

Nature microbiology·2026
Same author

Preclinical Pharmacokinetics and Pharmacodynamics of Antibiotic Adjuvants.

ACS infectious diseases·2026
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Dec 23, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.3K

Update on group A streptococcal vaccine development.

James B Dale1, Mark J Walker2

  • 1Division of Infectious Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Current Opinion in Infectious Diseases
|April 19, 2020
PubMed
Summary
This summary is machine-generated.

Developing effective group A streptococcus vaccines is crucial for global health. Recent advances in antigen discovery and vaccine design show promise, with combination vaccines demonstrating efficacy in preclinical models.

More Related Videos

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

14.8K
Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
09:25

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells

Published on: August 19, 2016

11.3K

Related Experiment Videos

Last Updated: Dec 23, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.3K
A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

14.8K
Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
09:25

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells

Published on: August 19, 2016

11.3K

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Microbial Pathogenesis

Background:

  • Group A Streptococcus (GAS) infections pose a significant global health burden, necessitating well-tolerated, effective, and affordable vaccines.
  • Current prevention strategies are limited, highlighting the urgent need for vaccine development against GAS and its severe complications.

Purpose of the Study:

  • To review recent advancements in identifying promising vaccine antigens for group A Streptococcus.
  • To explore novel vaccine design approaches addressing the complexities of GAS pathogenesis and epidemiology.

Main Methods:

  • Review of preclinical studies, including antigen discovery and formulation.
  • Analysis of efficacy data from animal models (mice, nonhuman primates).
  • Examination of early-stage human clinical trial data for multivalent M protein-based vaccines.

Main Results:

  • Combination vaccines with shared, cross-protective antigens show efficacy in preclinical models.
  • Multivalent M protein-based vaccines are advancing through clinical trials.
  • Enhanced immunogenicity observed with formulations containing universal T-cell epitopes and potent adjuvants.

Conclusions:

  • Significant progress in preclinical antigen discovery and vaccine formulation for group A Streptococcus.
  • Clinical development requires moving promising candidates forward to establish human efficacy.
  • Global efforts are underway to support the commercialization and licensure of GAS vaccines.